semaj83/ctmatch_classification huggingface dataset:
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 2.0-17.0,  Cerebral Palsy Spasticity Female or male subject of 2 to 17 years of age (inclusive) Uni or bilateral Cerebral Palsy (CP) with clinical need for injections with NT 201 for the treatment of upper limb (UL) spasticity at least unilaterally Ashworth Scale (AS) score in the main clinical target patterns in this study Flexed elbow: AS≥2 in elbow flexors (at least unilaterally). and/or Flexed Wrist: AS≥2 in wrist flexors (at least unilaterally) Clinical need according to the judgment of the investigator in one out of five treatment combinations (A-E, as shown below). AS score must be ≥2 for each target pattern chosen for injection at the Baseline Injection Visit V2 A. UL(s) treatment only (GMFCS I-V) A1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW)  Pre-treated (non-naïve) subjects must not have received BoNT treatment within the last 16 weeks prior to study treatment at V2 in any indication
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lower Limb Spasticity Men or women age 18 years and above Post-stroke lower-limb spasticity Prior agreement with the patient to inject BoNT-A If previously treated with BoNT-A, (at least 3 months interval between last injection and inclusion) Therapeutic goals agreed jointly with the patient Functional Ambulation Classification (FAC) score 2-5 Capacity to comply with the protocol Written informed consent  Documented positive antigenicity to botulinum toxin Neuromuscular disease Use of medications that interfere with neuromuscular transmission Severe muscle atrophy in any muscle to be injected Any other indication that might interfere with rehabilitation or the evaluation of results Any non-stroke spasticity diagnosis Pregnancy or nursing mothers Previous participation in any study using Goal Attainment Scale (GAS)
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Postoperative Cognitive Dysfunction Delirium Dementia Age ≥ 65 years Elective major surgery Planned general anesthesia  Cardiac surgery Neurosurgery including carotid endarterectomy Preoperative Mini Mental State (MMS) Examination Score < 24 Previous pathological neuroimaging (if available) History of cerebral or cerebrovascular pathology Chronic use of psychiatric medication Alcohol or substance abuse A history of chronic pain unrelated to the planned surgery Any contraindication for MRI (e.g. pacemakers and other MR-incompatible metal implants) Claustrophobia
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Induced Pluripotent Stem Cells OR THIRD PARTY (ALLOGENEIC CELLS, AND Subjects who meet ALL of the following will be considered for enrollment into this study Be greater than or equal to 18 years of age, as of the date of enrollment. There is no upper age limit for donor enrollment Able to provide informed consent Meets the donation requirements established by AABB and FDA for allogeneic or autologous use with the exception of hemoglobin/hematocrit  Subjects who meet ANY of the following will be excluded from participation in this study as a third party donor or research volunteer Medical history that includes any of the following, as per AABB or FDA requirements for allogeneic use Thrombocytopenia or other blood dyscrasias Bleeding diathesis Antibiotic use within the prior 48 hours History of cancer History of exposure to transfusion transmitted diseases including HIV and hepatitis B and C as defined by the Standards for Blood Banking and Transfusion Services, AABB Travel to an area where malaria is endemic as defined by the CDC (www.cdc.gov/travel) At risk for the possible transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) as described in the FDA Guidance for Industry, January 9, 2002, Revised Preventive Measures to Reduce the Possible Risk of Transfusion of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products Febr le (temperature > 38 (Infinite)C)
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Gaucher Disease Type 1 Age: >18 Gaucher disease type 1 Able to undergo a DEXA test  Minors
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Amyotrophic Lateral Sclerosis (ALS) Patients ≥18 years of age, diagnosed with ALS (<2 months before inclusion) according to Airlie House : definite, probable, or probable laboratory supported Time between first symptoms and diagnosis less than 18 months Sporadic or familial cases Patient agreement to be followed in a given ALS centre during the duration of the study Patients with a loss of at least 1 point in 3 items of the rating scale or with a loss of at least 2 points in 2 items of the rating scale Patients who signed the informed consent form  Associated dementia or inability to understand the requirements of the protocol No helper ONS already begun Artificial nutrition: enteral or parenteral nutrition Known hypersensitivity to components of ONS Absence of treatment with Riluzole (RILUTEK®) Patient under guardianship or curatorship Participation in another research protocol
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 30.0-75.0,  Stroke Paresis Motor deficits of the upper limb after a first ever stroke A minimum punctuation of 11 in the subtest from the Motricity Index and Trunk Control Test which evaluates grip and pinch Less than 6 months from stroke Age between 30 and 75 years Right-handed  Inability to speak and understand the Spanish or Catalan language Major cognitive impairment affecting comprehension Neurological or psychiatric co-morbidity Substance abuse Formal musical education (i.e. professional musicians) Metallic implants incompatible with neuroimaging assessment Withdrawal from the study Voluntary withdrawal of consent A new episode of stroke during the participation in the study
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Dementia Paratonia Severe cognitive impairment (complete dependency in all activities of daily living (ADLs) Diagnosis of Alzheimer's disease, vascular dementia,or frontotemporal dementia Score> 3 on the paratonic assessment instrument, with paratonic rigidity in an arm(s) interfering in the provision of care  Alternate etiologies for increased tone Botulinum toxin 6 months preceding the study
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Spasticity Men and women ≥ 18-80 years Poststroke limb spasticity Patients who have suffered a stroke in the previous 6 months Treatment goal has been previously agreed with the patient or their legal representative Patients with clinically significant poststroke upper/lower limb spasticity, in whom it has been decided to perform multidisciplinary treatment with BoNT-A + rehabilitation No previous treatment with BoNT-A Patient is able to follow the protocol Written informed consent  Neuromuscular disease Use of drugs that interfere with neuromuscular transmission Any other condition that could interfere with rehabilitation or evaluation of the results Diagnosis of spasticity not associated with stroke Pregnant or nursing mothers Prior participation in any other study in the 6 months before study entry
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Major Depressive Disorder Current DSM-IV diagnosis of MDD, unipolar type, without psychotic features and 6 weeks minimum duration of current depressive episode Moderate severity of depression using the Hamilton Depression Rating Scale (HDRS > 20) English speaking, male or female 65 years of age or older Good general health Able to give informed consent  Antidepressant use or psychotherapy within the past 6 weeks or electroconvulsive therapy within the past 6 months Recent history (<6 months) of substance or alcohol abuse or dependence (DSM-IV criteria) Use of cognitive enhancing medications Current diagnosis of Post-Traumatic Stress Disorder or other Axis 1 psychiatric disorder Neurological diseases (e.g., Parkinson's disease, epilepsy, cortical stroke, Alzheimer's disease, traumatic brain injury) or dementia History of surgical procedures affecting study outcomes Contraindications for MR exam, i.e., no claustrophobia, no paramagnetic metal implants, able to fit in the MRI machine comfortably (BMI ≤ 38) Acute or uncontrolled medical illness or medication use impacting cognitive function
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson's Disease Idiopathic Parkinson's Disease with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry Despite optimal pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonia or bradykinesia A life expectancy of at least two years  Age below 18 years Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy) Previous CLI (through a PEG-tube or Nasal Jejuna| tube) Hoehn and Yahr stage 5 at the best moment during the day Other severely disabling disease Dementia or signs of severe cognitive impairment Psychosis Current depression Contraindications for DBS surgery, such as a physical disorder making surgery hazardous Contraindications for PEG surgery such as interposed organs, ascites and oesophagogastric varices, or for Duodopa
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Leukoencephalopathy diagnosis of glioma (stage 3 to 4) both genders age > 18 years treatment by radiotherapy and chemotherapy clinical monitoring post radiotherapy in Neurology Department, Pitié-Salpêtrière University Hospital and in the radiotherapy department of the Paul Strauss Institute  other neurological tumors and brain metastases psychiatric severe illness, including severe depression
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  HIV - Human Immunodeficiency Virus Cognitive Impairment age 35 years or older HIV infection for at least 1 year able to communicate in English or French capable of providing informed consent easy access to the internet EEG and MRI compatible  presence of dementia life expectancy < 3 y other neurological disorder including active opportunistic CNS infection psychotic disorder current substance dependence or abuse; and Hepatitis C requiring interferon therapy during the study period
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cancer Rectal Cancer High-risk patients with biopsy proven rectal adenocarcinoma who will undergo long-course chemoradiotherapy (CRT) and who are potentially eligible for curative surgery Patients who have persistently (i.e. in baseline and post-treatment MRI) mrEMVI positive (with superior rectal vein invasion) or mrEMVI negative tumours Patients aged over 18 years Negative (on CT) for metastatic disease  Under 18 years of age Patients with any metastatic disease Patients with a synchronous second malignancy
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Multiple Sclerosis 55 inclusive years of age at the time of informed consent Diagnosis of relapsing multiple sclerosis as defined by the 2010 revised McDonald Currently taking Tysabri  Systemic steroid users comorbidities that could confound MRI outcomes
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 35.0-75.0,  Parkinson Disease Dementia Age at the time of enrollment: 35 years Diagnosis of idiopathic PD with probable Parkinson's disease dementia (PDD) as defined by the MDS consensus guidelines (Emre et al., 2007) Mild to moderately severe dementia as defined by a Mini-Mental State Examination (MMSE) score of 10 to 24 Duration of bilateral idiopathic PD: ≥5 years of motor symptoms Severity of bilateral idiopathic PD in the meds off state: modified Hoehn and Yahr stage ≥2 UPDRS subset III score of ≥30 in the meds off, stim off state Levodopa must improve PD symptoms by ≥30% in a levodopa challenge test, as measured by UPDRS subset III score PDD with a symptom onset at least 2 years after first symptoms of PD Be willing and able to comply with all visits and study related procedures (e.g., using the remote control, charging systems and completing the motor diary) if mentally competent or, if incompetent, their legally authorized representatives  Any significant psychiatric problems, including acute confusional state (delirium), ongoing psychosis, or clinically significant depression Any current drug or alcohol abuse Any history of recurrent or unprovoked seizures Any prior movement disorder treatments that involved intracranial surgery or device implantation A history of neurostimulation intolerance in any area of the body Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival <12 months Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. Any other trial participation should be approved by the Principal Investigators Pregnancy, breast-feeding, or lack of reliable contraception
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hereditary Spastic Paraplegia Age between 18 and 80 years Clinical diagnosis of Hereditary Spastic Paraplegia Ability to walk at least 10 meters: Assistive devices are permitted  Wheelchair bound patients Additional neurological symptoms that may significantly impact gait such as ataxia, polyneuropathy or dementia Fixed tendon contractures Antecedents of allergy or adverse reaction to botulinum toxin Pregnancy or breastfeeding condition Mental retardation Dementia
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 45.0-80.0,  Colon Cancer Polyps Patients who are 45 to 80 years old for routine screening colonoscopy  Patients with inflammatory bowel disease Patients with polyposis syndromes Pregnant women Patients over 350 pounds Patients with bright red blood per rectum Patients who have a contraindication to undergo outpatient colonoscopy, including patients on blood thinners, prior myocardial infarction (MI) in the last six months, history of congestive heart failure (CHF), history of arrhythmia, patients too weak to transfer themselves from a bed to a chair, or patients with severe constipation who would require a two day bowel preparation All subjects will undergo informed consent by the St. Luke’s institutional review board (IRB). Referred subjects will be asked if they are interested in the study and those responding affirmatively will be transferred to a recruiter to learn about the study and begin the consent process if interested
Patient description: A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Polyps Patients: over 18 years of age, with clinical indication for colonoscopy who are considered by the endoscopist to be fit for the procedure Endoscopists who have started colonoscopy training on a recognised training rotation. Consultants who perform colonoscopy regularly  patients under 18 years, patients with previous colorectal surgery or known familial polyposis, patients unable to give informed consent, pregnant patients, patients for whom coloscope insertion was difficult or uncomfortable, patients whose colon is not sufficiently cleared of stool, those unwilling to participate